ARMANDO ANIDO - 18 Jul 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role
Chairman & CEO, Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Jul 2022
Net transactions value
-$13,089
Form type
4
Filing time
20 Jul 2022, 16:05:23 UTC
Previous filing
22 Jun 2022
Next filing
25 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +43,164 +7.4% 623,587 18 Jul 2022 Direct F1
transaction ZYNE Common Stock Sale $13,089 -11,899 -1.9% $1.10 611,688 19 Jul 2022 Direct F2
holding ZYNE Common Stock 26,595 18 Jul 2022 See footnote F3
holding ZYNE Common Stock 13,297 18 Jul 2022 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 43,164 performance-based restricted stock awards granted in a prior year.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.